Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

An Analysis of Adherence to Melanoma Treatment

J Clin Aesthet Dermatol; 2017 Dec; Reserva, et al

A recent study’s findings highlight some variables associated with poor surveillance adherence among melanoma survivors that could help to guide efforts in counseling this at-risk population. Researchers retrospectively reviewed the initial 5-year dermatology follow-up visit frequencies of melanoma patients and extracted basic demographic and clinical data from their medical records. Of 186 patients included, the mean age was 55 (SD=15); 47.5% (n=85) were female, 93% (n=173) were white, and 76.2% (n=141) were married; 60% lived at locations >10 miles from the clinic, and 58.6% had private insurance. They found:

  • Between 58.4 and 74.5% of patients adhered to “aggressive” surveillance, with decreasing rates over the 5-year period.
  • Annual rates of poor surveillance adherence (7.3–23.6%) increased over time.
  • Based on adjusted odds ratios, patients aged <50 years, those lacking health insurance, and those with at least Stage IIB disease are more likely to be poorly adherent to melanoma surveillance.

Reserva J, Janeczek M, Joyce C, et al. A retrospective analysis of surveillance adherence of patients after treatment of primary cutaneous melanoma. 2017;10(12):44-48. J Clin Aesthet Dermatol.